Central Centrifugal Cicatricial Alopecia Clinical Trial
— CCCAOfficial title:
A Pilot Study of Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
Verified date | August 2023 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2023 |
Est. primary completion date | November 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Women who are eighteen years of age or older - biopsy-proven and/or clinical diagnosis of CCCA Stage II-IV - must be on stable treatment without changes for at least 3 months - Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology. Exclusion Criteria: - Males |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of hairline stabilization | Standardized camera and dermatoscopic photographs | Baseline | |
Primary | Amount of hairline stabilization | Standardized camera and dermatoscopic photographs | Month 2 | |
Primary | Amount of hairline stabilization | Standardized camera and dermatoscopic photographs | Month 4 | |
Primary | Amount of hairline stabilization | Standardized camera and dermatoscopic photographs | Month 6 | |
Secondary | Amount of hair regrowth | Standardized camera and dermatoscopic photographs | Baseline, Month 2, Month 4, and Month 6 | |
Secondary | Signs and symptoms of disease score | standardized questionnaire - higher scores denotes worse condition | Month 2, Month 4, and Month 6 | |
Secondary | Dermatology Life Quality Index score | scores of "not at all" to "very much" | Baseline and Month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03521687 -
Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
|
Phase 4 | |
Not yet recruiting |
NCT05416333 -
Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
|
Early Phase 1 | |
Recruiting |
NCT04764331 -
A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
|
N/A | |
Recruiting |
NCT05759338 -
A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
|
N/A | |
Completed |
NCT03346668 -
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
|
Early Phase 1 | |
Completed |
NCT03044782 -
Barriers to Care and QOL for CCCA Patients
|
N/A | |
Completed |
NCT04342091 -
Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
|
N/A |